Literature DB >> 12801599

Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance.

Michael H Ossipov1, Josephine Lai, Todd W Vanderah, Frank Porreca.   

Abstract

Opioid analgesics are frequently used for the long-term management of chronic pain states, including cancer pain. The prolonged use of opioids is associated with a requirement for increasing doses to manage pain at a consistent level, reflecting the phenomenon of analgesic tolerance. It is now becoming clearer that patients receiving long-term opioid therapy can develop unexpected abnormal pain. Such paradoxical opioid-induced pain, as well as tolerance to the antinociceptive actions of opioids, has been reliably measured in animals during the period of continuous opioid delivery. Several recent studies have demonstrated that such pain may be secondary to neuroplastic changes that result, in part, from an activation of descending pain facilitation mechanisms arising from the rostral ventromedial medulla (RVM). One mechanism which may mediate such pain facilitation is through the increased activity of CCK in the RVM. Secondary consequences from descending facilitation may be produced. For example, opioid-induced upregulation of spinal dynorphin levels seem to depend on intact descending pathways from the RVM reflecting spinal neuroplasticity secondary to changes at supraspinal levels. Increased expression of spinal dynorphin reflects a trophic action of sustained opioid exposure which promotes an increased pain state. Spinal dynorphin may promote pain, in part, by enhancing the evoked release of excitatory transmitters from primary afferents. In this regard, opioids also produce trophic actions by increasing CGRP expression in the dorsal root ganglia. Increased pain elicited by opioids is a critical factor in the behavioral manifestation of opioid tolerance as manipulations which block abnormal pain also block antinociceptive tolerance. Manipulations that have blocked enhanced pain and antinociceptive tolerance include reversible and permanent ablation of descending facilitation from the RVM. Thus, opioids elicit systems-level adaptations resulting in pain due to descending facilitation, upregulation of spinal dynorphin and enhanced release of excitatory transmitters from primary afferents. Adaptive changes produced by sustained opioid exposure including trophic effects to enhance pain transmitters suggest the need for careful evaluation of the consequences of long-term opioid administration to patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801599     DOI: 10.1016/s0024-3205(03)00410-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  36 in total

1.  Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity.

Authors:  Bo Lian; Louis Vera-Portocarrero; Tamara King; Michael H Ossipov; Frank Porreca
Journal:  Brain Res       Date:  2010-08-19       Impact factor: 3.252

2.  Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila I Keresztes; Takashi Yamamoto; Todd W Vanderah; William R Roeske; Victor J Hruby; Eva V Varga
Journal:  Eur J Pharmacol       Date:  2012-06-05       Impact factor: 4.432

3.  Control of chronic pain by the ubiquitin proteasome system in the spinal cord.

Authors:  Michael H Ossipov; Igor Bazov; Luis R Gardell; Justin Kowal; Tatiana Yakovleva; Ivan Usynin; Tomas J Ekström; Frank Porreca; Georgy Bakalkin
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 4.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

5.  [Anesthesia and analgesia in addicts: basis for establishing a standard operating procedure].

Authors:  J Jage; F Heid
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

6.  Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity.

Authors:  Amina S Woods; Rafal Kaminski; Murat Oz; Yun Wang; Kurt Hauser; Robin Goody; Hay-Yan J Wang; Shelley N Jackson; Peter Zeitz; Karla P Zeitz; Dorota Zolkowska; Raf Schepers; Michael Nold; Jens Danielson; Astrid Gräslund; Vladana Vukojevic; Georgy Bakalkin; Allan Basbaum; Toni Shippenberg
Journal:  J Proteome Res       Date:  2006-04       Impact factor: 4.466

Review 7.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

8.  Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.

Authors:  N S Abul-Husn; M Sutak; B Milne; K Jhamandas
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

9.  Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons.

Authors:  Akiko Okada-Ogawa; Frank Porreca; Ian D Meng
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

10.  NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice.

Authors:  T Doyle; E Esposito; L Bryant; S Cuzzocrea; D Salvemini
Journal:  Neuroscience       Date:  2013-02-27       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.